Teon Therapeutics a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and development of G-Protein Coupled Receptor immuno-oncology therapies in difficult-to-treat cancers, has entered into the clinical trial collaboration agreement with Merck (NYSE: MRK), an in immuno-oncology company.

The agreement is for the combination arm of Teon’s ongoing, two-armed, open-label, dose escalation and expansion clinical study and will evaluate Teon’s oral, immune response modifier, TT-816, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for patients with advanced solid tumors. The study will include patients with many difficult-to-treat cancers with high unmet medical need who have not responded to the standard-of-care and may have limited treatment options.

“We are fortunate to have the opportunity to collaborate with Merck for this phase 1/2 trial. The collaboration of the combination arm of our TT-816 clinical trial represents an important advancement in our comprehensive development program …

Full story available on Benzinga.com